medigraphic.com
ISSN 0016-3813 (Print)

2009, Number 1

<< Back Next >>

Gac Med Mex 2009; 145 (1)

Bacteremia por Acinetobacter baumannii en pacientes en estado crítico

Aguirre-Ávalos G, Mijangos-Méndez JC, Zavala-Silva ML, Coronado-Magaña H, Amaya-Tapia G

Language: Spanish
References: 30
Page: 21-26
PDF size: 85.87 Kb.


ABSTRACT

Objective: Determine the severity and the course of Acinetobacter baumannii blood infections (AbBI). Methods: We carried out a prospective review of all Acinetobacter baumannii (A.baumannii) isolated from the Intensive Care Unit ICU) of a medical facility.Results: During the study period, 46 patients were identified with AbBI. The rate of AbBI was 14 per 1,000 admissions. A.baumannii was ICU acquired in 85% of cases studied. The median time frame between ICU admission and acquisition of AbBI was 9±7 days. 31 patients displayed blood infection (BI) by A.baumannii alone and 15 with polymicrobial BI. The clinical manifestation of the 31 patients with AbBI included the following symptoms: 42% presented with septic shock, 42% had severe sepsis and 16% had sepsis. Two or more episodes of AbBI were observed among 13% of patients. Of A.baumannii isolates, 17% were resistant to imipenem. Patient mortality with AbBI alone was 45% and 40% for polymicrobial BI. Patient mortality for septic shock was 60%, 70% died during the first 72 hrs after AbBI.Conclusions: AbBI displayed an endemic pattern during the studyperiod. Severe sepsis and septic shock were the most common clinical presentations of AbBI. AbBI are associated with a significant increase in the death rate of patient in the ICU studied.


REFERENCES

  1. Villegas MV, Hartstein AI. Acinetobacter outbreaks, 1977-2000. Infect Control Hosp Epidemiol 2003;24:284-295.

  2. Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis 2006;42:692-699.

  3. Seifert H, Strate A, Pulverer G. Nosocomial bacteremia due to Acinetobacter baumannii: Clinical features, epidemiology, and predictors of mortality. Medicine 1995;74:340-349.

  4. Siau H, Yuen KY, Ho PL, Wong SS, Woo PC. Acinetobacter bacteremia in Hong Kong: Prospective study and review. Clin Infect Dis 1999;28:26-30.

  5. Wisplinghoff H, Edmond MB, Pfaller MA, Jones RN, Wenzel RP, Seifert H. Nosocomial bloodstream infections caused by Acinetobacter species in United States hospital: Clinical features, molecular epidemiology, and antimicrobial susceptibility. Clin Infect Dis 2000;31:690-697.

  6. Choi SH, Chou EJ, Kwak YG, Kim MY, Jun JB, Kim MN et al. Clinical characteristics and outcomes of bacteremia caused by Acinetobacter species other than A. baumannii: Comparison with A. baumannii bacteremia. J Infect Chemother 2006;12:380-386.

  7. Basustaoglu AC, Kisa O, Sacilik SC, Ozyurt M, Yildiran ST. Epidemiological characterization of hospital-acquired Acinetobacter baumannii isolates from a 1500-bed teaching hospital by phenotypic and genotypic methods. J Hosp Infect 2001;47:246-249.

  8. García-Garmendia JL, Ortiz-Leyva C, Garnacho-Montero J, Jiménez-Jiménez FJ, Pérez-Paredes C, Barrero-Almodóvar AE, et al. Risk factors for Acinetobacter baumannii nosocomial bacteremia in critically ill patients: A cohort study. Clin Infect Dis 2001;33:939-946.

  9. Villers D, Espaze E, Coste-Burel M, Giauffret F, Ninin E, Nicolas F, et al.Nosocomial Acinetobacter baumannii infections. Microbiological and clinical epidemiology. Ann Intern Med 1998;129:182-189.

  10. Chen HP, Chen TL, Lai CH, Fung CP, Wong WW, Yu KW, et al. Predictors of mortality in Acinetobacter baumannii bacteremia. J Microbiol Immunol Infect 2005; 38:127-136.

  11. Kuo LC, Lai CC, Liao CH, Hsu CK, Chang YL, Chang CY, et al. Multidrugresistant Acinetobacter baumannii bacteraemia: Clinical features, antimicrobial therapy and outcome. Clin Microbiol Infect 2007;13:196-198.

  12. Blot S, Vandewoude K, Colardyn F. Nosocomial bacteremia involving Acinetobacter baumanii in critically ill patients: A matched cohort study. Intensive Care Med 2003;294:471-475.

  13. Cisneros JM, Reyes MJ, Pachón J, Becerril B, Caballero FJ, García-Garmendia JL, et al. Bacteremia due to Acinetobacter baumannii: Epidemiology, clinical findings, and prognostic features. Clin Infect Dis 1996;22:1026-1032.

  14. Vallés J, León C, Álvarez-Lerma F. Nosocomial bacteremia in critically ill patients: A multicenter study evaluating epidemiology and Prognosis. Clin Infect Dis 1997;24:387-395.

  15. Wisplinghoff H, Perbix W, Seifert H. Risk factors for nosocomial bloodstream infections due to Acinetobacter baumannii: A case-control study of adult burn patients. Clin Infect Dis 1999;28:59-66.

  16. García-Garmendia JL, Ortiz-Leyva C, Garnacho-Montero J, Jiménez-Jiménez FJ, Monterrubio-Villar J, Gili-Miner M. Mortality and the increase in length of stay attributable to the acquisition of Acinetobacter in critically ill patients. Crit Care Med 1999;27:1794-1799.

  17. Wang JT, McDonald LC, Chang SC, Ho M. Community-acquired Acinetobacter baumannii bacteremia in adult patients in Taiwan. J Clin Microbiol 2002;40:1526-1529.

  18. Nan-Yao L, Hsin-Chun L, Nai-Ying K, Chia-Ming C, Hsin-I S, Chi-Jung W,et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol 2007;28:713-719.

  19. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864-874.

  20. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250-1256.

  21. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections 1988. Am J Infect Control 1988;16:128-140.

  22. Horan TC, Gaynes RP. Surveillance of nosocomial infections. En: Hospital Epidemiology and Infection Control. 3rd ed. Philadelphia: Lippincott Williams & Wilkins; 2004. pp. 1659-1702.

  23. Norma Oficial Mexicana de Emergencia NOM-EM-002-SSA2-2003, para la vigilancia epidemiológica, prevención y control de las infecciones nosocomiales. Disponible en http://www.salud.gob.mx/unidades/cdi/nom/em002ssa203.html

  24. Šulgajic V, Cobeljic M, Jankovic S, Mirovic V, Markivic-Denic L, Romic P,et al. Nosocomial bloodstream infections in ICU and non-ICU patients. Am J Infect Control 2005;33:333-340.

  25. Hsueh PR, Teng LJ, Chen CY, Chen WH, Yu CJ, Ho SW, et al. Pandrugresistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan. Emerg Infect Dis 2002;8:827-832.

  26. Aguirre-Ávalos G, Quintero-Rojas MV, Corona-García V, Zavala-Silva ML,Coronado-Magaña H, Rodríguez-Hinojosa, et al. Multidrug-resistant Acinetobacter baumannii infections from critically ill patients. Abstract. En: The 41st Annual Meeting of IDSA, October 9-12, 2003, San Diego, California, USA.

  27. Aguirre-Ávalos G, Mijangos-Méndez JC, Duéñez-Estrella BJ, Vázquez-Díaz JO, Gutiérrez-Sierra JA, Robles-Ramírez K, et al. Severity of Acinetobacter baumannii blood infections in critically ill patients. Abstract. En: The 44th Annual Meeting of IDSA, October 12-15, 2006, Toronto, Ontario, Canada.

  28. McDonald LC, Banerjee SN, Jarvis WR, and the National Nosocomial Infections Surveillance System. Seasonal variation of Acinetobacter Infections: 1987-1996. Clin Infect Dis 1999;29:1133-1137.

  29. Fillaux J, Dubuoix A, Conil JM, Laguerre J, Marty N. Retrospective analysis of multidrug-resistant Acinetobacter baumannii strains isolated during a 4-year period in a university hospital. Infect Control Hosp Epidemiol 2006;27:647-653.

  30. Jiménez-Mejías ME, Pachón J, Becerril B, Palomino-Nicas J, Rodríguez-Cobacho A, Revuelta M. Treatment of multidrug-resistant Acinetobacter baumannii meningitis with ampicillin/sulbactam. Clin Infect Dis 1997;24:932-935.




2020     |     www.medigraphic.com